How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors

Poly(ADP-ribose)polymerase (PARP) inhibitors are targeted therapy for cancers with homologous repair deficiency (HRD). They were first approved for ovarian cancer and have changed current treatment strategies. They have also demonstrated efficacy in HER2-negative metastatic breast cancer and advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Neviere, Zoé, De La Motte Rouge, Thibault, Floquet, Anne, Johnson, Alison, Berthet, Pascaline, Joly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052467/
https://www.ncbi.nlm.nih.gov/pubmed/32165926
http://dx.doi.org/10.1177/1758835919897530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052467/
https://www.ncbi.nlm.nih.gov/pubmed/32165926
http://dx.doi.org/10.1177/1758835919897530

Ejemplares similares